{"id":"progabide","rwe":[],"tags":[{"label":"progabide","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"GABA-A receptor; anion channel","category":"target"},{"label":"GABRA1","category":"gene"},{"label":"GABRA2","category":"gene"},{"label":"GABRA3","category":"gene"},{"label":"N03AG05","category":"atc"},{"label":"Active","category":"status"},{"label":"Anti-Dyskinesia Agents","category":"pharmacology"},{"label":"Anticonvulsants","category":"pharmacology"},{"label":"Antidepressive Agents","category":"pharmacology"},{"label":"Antiparkinson Agents","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"GABA Agents","category":"pharmacology"},{"label":"GABA Agonists","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Psychotropic Drugs","category":"pharmacology"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"gabren","offLabel":[],"synonyms":["progabide","halogabide","gabrene","gabren"],"timeline":[{"date":"1985-01-01","type":"positive","source":"DrugCentral","milestone":"YEAR INTRODUCED approval"}],"aiSummary":"Gabren, also known as Progabide, is a small molecule drug that targets the GABA-A receptor, an anion channel. It is a progabide drug class, but its commercial status and approved indications are unknown. The drug has a bioavailability of 60%, but its half-life and generic manufacturers are not specified. As a result, its current owner and off-patent status are also unclear. Further research is needed to determine its clinical use and safety profile.","approvals":[{"date":"1985-01-01","orphan":false,"company":"","regulator":"YEAR INTRODUCED"}],"brandName":"Gabren","ecosystem":[],"mechanism":{"target":"GABA-A receptor alpha-1/beta-2/gamma-2, GABA-A receptor; anion channel, GABA-A receptor; anion channel","targets":[{"gene":"GABRA1","source":"DrugCentral","target":"GABA-A receptor; anion channel","protein":"Gamma-aminobutyric acid receptor subunit alpha-1"},{"gene":"GABRA2","source":"DrugCentral","target":"GABA-A receptor; anion channel","protein":"Gamma-aminobutyric acid receptor subunit alpha-2"},{"gene":"GABRA3","source":"DrugCentral","target":"GABA-A receptor; anion channel","protein":"Gamma-aminobutyric acid receptor subunit alpha-3"},{"gene":"GABRA4","source":"DrugCentral","target":"GABA-A receptor; anion channel","protein":"Gamma-aminobutyric acid receptor subunit alpha-4"},{"gene":"GABRA5","source":"DrugCentral","target":"GABA-A receptor; anion channel","protein":"Gamma-aminobutyric acid receptor subunit alpha-5"},{"gene":"GABRA6","source":"DrugCentral","target":"GABA-A receptor; anion channel","protein":"Gamma-aminobutyric acid receptor subunit alpha-6"},{"gene":"GABRB1","source":"DrugCentral","target":"GABA-A receptor; anion channel","protein":"Gamma-aminobutyric acid receptor subunit beta-1"},{"gene":"GABRB2","source":"DrugCentral","target":"GABA-A receptor; anion channel","protein":"Gamma-aminobutyric acid receptor subunit beta-2"},{"gene":"GABRB3","source":"DrugCentral","target":"GABA-A receptor; anion channel","protein":"Gamma-aminobutyric acid receptor subunit beta-3"},{"gene":"GABRD","source":"DrugCentral","target":"GABA-A receptor; anion channel","protein":"Gamma-aminobutyric acid receptor subunit delta"}],"modality":"Small Molecule","drugClass":"progabide","explanation":"Think of GABA like a brake pedal in a car. When GABA binds to its receptors, it helps to slow down the activity of neurons, which can help to reduce anxiety, seizures, and other conditions. Gabren increases the effectiveness of GABA, allowing it to bind more easily to its receptors and produce a calming effect.","oneSentence":"Gabren works by enhancing the activity of the neurotransmitter GABA, which helps to calm down excessive neuronal activity in the brain.","technicalDetail":"Gabren acts as a positive allosteric modulator of the GABA-A receptor, increasing the frequency of chloride channel opening and enhancing the inhibitory effects of GABA on neuronal activity."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2278","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PROGABIDE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:26:20.975380","biosimilars":[],"competitors":[{"drugName":"valproic acid","drugSlug":"valproic-acid","fdaApproval":"1978-02-28","genericCount":14,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"aminobutyric acid","drugSlug":"aminobutyric-acid","fdaApproval":"","relationship":"same-class"},{"drugName":"vigabatrin","drugSlug":"vigabatrin","fdaApproval":"2009-08-21","patentExpiry":"Oct 17, 2042","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"tiagabine","drugSlug":"tiagabine","fdaApproval":"1997-09-30","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"progabide","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"valproic-acid","brandName":"valproic acid","genericName":"valproic acid","approvalYear":"1978","relationship":"same-class"},{"drugId":"aminobutyric-acid","brandName":"aminobutyric acid","genericName":"aminobutyric acid","approvalYear":"","relationship":"same-class"},{"drugId":"vigabatrin","brandName":"vigabatrin","genericName":"vigabatrin","approvalYear":"2009","relationship":"same-class"},{"drugId":"tiagabine","brandName":"tiagabine","genericName":"tiagabine","approvalYear":"1997","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NDDF":"005334","UNII":"38C836J57Z","CHEBI":"CHEBI:135422","INN_ID":"4656","RXNORM":"34568","UMLSCUI":"C0072076","ChEMBL_ID":"CHEMBL287631","KEGG_DRUG":"D05621","DRUGBANK_ID":"DB00837","PUBCHEM_CID":"44115","MESH_SUPPLEMENTAL_RECORD_UI":"C017985"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"60%"},"publicationCount":197,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"N03AG05","allCodes":["N03AG05"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"OTHER","regulator":"YEAR INTRODUCED","status":"approved","approval_date":"1985-01-01T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"enriching","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}